Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to -$106000.0.

  • Harmony Biosciences Holdings' Non Operating Income rose 1451.61% to -$106000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$415000.0, marking a year-over-year decrease of 108571.43%. This contributed to the annual value of -$68000.0 for FY2024, which is 14276.73% down from last year.
  • Harmony Biosciences Holdings' Non Operating Income amounted to -$106000.0 in Q3 2025, which was up 1451.61% from -$193000.0 recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Non Operating Income registered a high of $193000.0 during Q4 2023, and its lowest value of -$276000.0 during Q1 2025.
  • Moreover, its 5-year median value for Non Operating Income was $0.0 (2022), whereas its average is -$16666.7.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Non Operating Income soared by 95000.0% in 2022 and then plummeted by 715000.0% in 2024.
  • Harmony Biosciences Holdings' Non Operating Income (Quarter) stood at $31000.0 in 2021, then surged by 135.48% to $73000.0 in 2022, then surged by 164.38% to $193000.0 in 2023, then dropped by 17.1% to $160000.0 in 2024, then plummeted by 166.25% to -$106000.0 in 2025.
  • Its Non Operating Income stands at -$106000.0 for Q3 2025, versus -$193000.0 for Q2 2025 and -$276000.0 for Q1 2025.